Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

, BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

08:20
11/23/16
11/23
08:20
11/23/16
08:20

Kite Pharma, other CAR-T stocks fall after Juno puts trial on hold

Shares of Juno Therapeutics (JUNO) remain halted in pre-market trading after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015, known as the "ROCKET" trial, after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover, Juno said. Other companies working on "CAR-T" therapies, a new class of oncology drugs that reengineer a patient's own cells to attack the disease, include Kite Pharma (KITE), which is down more than 6%, as well as ZIOPHARM Oncology(ZIOP) and bluebird bio (BLUE), which are each down nearly 6%. Juno shares are expected to resume trading at 8:30 am ET, according to Nasdaq.

KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

ZIOP

Ziopharm

$6.14

-0.27 (-4.21%)

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 03

    Dec

KITE Kite Pharma
$51.69

-1.99 (-3.71%)

11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/04/16
MAXM
11/04/16
NO CHANGE
Target $57
MAXM
Buy
bluebird bio price target lowered to $57 from $100 at Maxim
After bluebird released abstracts to be presented at the American Society of Hematology meeting in December, Maxim analyst Jason McCarthy said the "long-awaited" data for the next seven patients in the sickle cell study failed to impress, noting that the median vector copy number of corrected hemoglobin is low. Given expectations for longer timelines to get to Proof of Concept data in sickle cell, McCarthy has pushed back his expectations for a commercial launch in sickle cell to 2022 from 2020 and lowered his price target to $57 from $100, but given the potential in other program and the current valuation, he keeps a Buy rating on bluebird shares.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
BMO Capital initiated bluebird bio with a Market Perform rating and $61 price target.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
Analyst Matthew Luchini initiated bluebird with a Market Perform and a $61 price target.
11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ZIOP Ziopharm
$6.14

-0.27 (-4.21%)

12/04/15
12/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affimed Therapeutics (AFMD) initiated with an Outperform at Wells Fargo... American Farmland (AFCO) initiated with an Outperform at Raymond James... Amgen (AMGN) initiated with a Market Perform at Wells Fargo... Applied Genetic (AGTC) initiated with an Outperform at Wells Fargo... BCE (BCE) initiated with a Buy at Goldman... Capital Product (CPLP) initiated with a Buy at Janney Capital... Celestica (CLS) initiated with a Neutral at B. Riley... Colfax (CFX) initiated with a Perform at Oppenheimer... Dimension Therapeutics (DMTX) initiated with an Outperform at Wells Fargo... Dover (DOV) initiated with a Perform at Oppenheimer... Fate Therapeutics (FATE) initiated with an Outperform at Wells Fargo... FibroGen (FGEN) initiated with a Buy at Citi... Finish Line (FINL) initiated with a Hold at BB&T... Five Prime (FPRX) resumed with an Outperform at Wells Fargo... Foot Locker (FL) initiated with a Buy at BB&T... GWG Holdings (GWGH) initiated with a Buy at Roth Capital... General Growth (GGP) initiated with an Outperform at Boenning & Scattergood... GigOptix (GIG) initiated with a Buy at Sterne Agee CRT... Halozyme (HALO) initiated with an Outperform at Wells Fargo... Hasbro (HAS) initiated with a Hold at Jefferies... Infinera (INFN) initiated with an Outperform at Raymond James... Inphi (IPHI) initiated with a Buy at Sterne Agee CRT... Inter Parfums (IPAR) initiated with an Overweight at KeyBanc... Intercept (ICPT) initiated with a Market Perform at Wells Fargo... Isis Pharmaceuticals (ISIS) initiated with an Outperform at Wells Fargo... LinkedIn (LNKD) initiated with a Buy at Nomura... Macerich (MAC) initiated with an Outperform at Boenning & Scattergood... Markit (MRKT) initiated with a Hold at Cantor... Mattel (MAT) initiated with a Buy at Jefferies... Maximus (MMS) initiated with a Buy at Stifel... MyoKardia (MYOK) initiated with an Outperform at Wells Fargo... Nimble Storage (NMBL) initiated with an Overweight at JPMorgan... OncoMed (OMED) initiated with an Outperform at Wells Fargo... Patriot National (PN) initiated with a Buy at Compass Point... Pennsylvania REIT (PEI) initiated with a Neutral at Boenning & Scattergood... Pixelworks (PXLW) initiated with a Buy at Craig-Hallum... Qualcomm (QCOM) initiated with an Overweight at Pacific Crest... Regeneron (REGN) initiated with an Outperform at Wells Fargo... Regulus (RGLS) initiated with an Outperform at Wells Fargo... Rogers Communications (RCI) initiated with a Neutral at Goldman... Rouse Properties (RSE) initiated with a Neutral at Boenning & Scattergood... Sangamo (SGMO) initiated with an Outperform at Wells Fargo... Sanmina (SANM) initiated with a Buy at B. Riley... Simon Property (SPG) initiated with an Outperform at Boenning & Scattergood... TELUS (TU) initiated with a Neutral at Goldman... TESARO (TSRO) initiated with an Outperform at Wells Fargo... Tokai Pharmaceuticals (TKAI) initiated with an Outperform at Wells Fargo... Vitae Pharmaceuticals (VTAE) initiated with an Outperform at Wells Fargo... ZIOPHARM (ZIOP) initiated with an Underperform at Wells Fargo... bluebird bio (BLUE) initiated with an Outperform at Wells Fargo.
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
ZIOPHARM initiated with a Market Perform at Raymond James
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
08/10/16
WELS
08/10/16
UPGRADE
WELS
Market Perform
ZIOPHARM upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded ZIOPHARM Oncology to Market Perform citing valuation following the company's Q2 results. The analyst keeps a $5-$8 price target range for the shares.
JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/03/16
BTIG
11/03/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
11/04/16
BTIG
11/04/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
BTIG analyst Dane Leone upgraded Juno Therapeutics (JUNO) to Neutral from Sell citing valuation following the ASH abstract release showed similar response rates for JCAR017 versus Kite's (KITE) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma.

TODAY'S FREE FLY STORIES

10:02
09/21/17
09/21
10:02
09/21/17
10:02
General news
Leading Indicators data reported »

August Leading Indicators…

GLD

SPDR Gold Trust

$122.83

-0.79 (-0.64%)

10:01
09/21/17
09/21
10:01
09/21/17
10:01
Options
One-day put seller in SPDR Gold Fund »

One-day put seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:00
09/21/17
09/21
10:00
09/21/17
10:00
General news
Fed funds futures are little changed inside a very narrow trading ranges »

Fed funds futures are…

ARI

Apollo Commercial

$18.35

0.065 (0.36%)

09:59
09/21/17
09/21
09:59
09/21/17
09:59
Conference/Events
Apollo Commercial management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ALB

Albemarle

$135.68

-0.405 (-0.30%)

09:59
09/21/17
09/21
09:59
09/21/17
09:59
Conference/Events
Albemarle management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

AFSI

AmTrust

$12.90

0.01 (0.08%)

09:57
09/21/17
09/21
09:57
09/21/17
09:57
Conference/Events
AmTrust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AAPL

Apple

$156.07

-2.66 (-1.68%)

09:57
09/21/17
09/21
09:57
09/21/17
09:57
Technical Analysis
Technical View: Apple edges below uptrend support line »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AR

Antero Resources

$20.21

-0.09 (-0.44%)

09:56
09/21/17
09/21
09:56
09/21/17
09:56
Downgrade
Antero Resources rating change  »

Antero Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$50.66

0.12 (0.24%)

09:55
09/21/17
09/21
09:55
09/21/17
09:55
Hot Stocks
Alkermes CEO highlights study showing opioids reduce life expectancy »

Alkermes CEO Richard Pops…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

APC

Anadarko

$47.29

2.48 (5.53%)

, PEG

PSEG

$45.88

0.645 (1.43%)

09:55
09/21/17
09/21
09:55
09/21/17
09:55
Options
Early notable gainers among liquid option names on September 21st »

Notable gainers among…

APC

Anadarko

$47.29

2.48 (5.53%)

PEG

PSEG

$45.88

0.645 (1.43%)

SLG

SL Green Realty

$98.99

1.27 (1.30%)

TSS

TSYS

$68.28

0.83 (1.23%)

CF

CF Industries

$35.50

0.31 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 27

    Sep

  • 05

    Nov

AMD

AMD

$13.74

0.62 (4.73%)

09:53
09/21/17
09/21
09:53
09/21/17
09:53
Options
Flurry of activity in AMD calls early-Thursday »

Flurry of activity in AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMP

Oasis Midstream Partners

, OAS

Oasis Petroleum

$8.83

-0.085 (-0.95%)

09:51
09/21/17
09/21
09:51
09/21/17
09:51
Syndicate
Breaking Syndicate news story on Oasis Midstream Partners, Oasis Petroleum »

Oasis Midstream Partners…

OMP

Oasis Midstream Partners

OAS

Oasis Petroleum

$8.83

-0.085 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 21

    Sep

KEG

Key Energy

$12.59

-0.05 (-0.40%)

09:50
09/21/17
09/21
09:50
09/21/17
09:50
Initiation
Key Energy initiated  »

Key Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXPE

Expedia

$143.01

1.54 (1.09%)

, GOOG

Alphabet

$931.58

9.77 (1.06%)

09:49
09/21/17
09/21
09:49
09/21/17
09:49
Periodicals
Expedia CEO says HomeAway unit profit goal may need shifting, Skift reports »

Expedia (EXPE) CEO Mark…

EXPE

Expedia

$143.01

1.54 (1.09%)

GOOG

Alphabet

$931.58

9.77 (1.06%)

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

AMZN

Amazon.com

$973.21

3.35 (0.35%)

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

AAPL

Apple

$156.07

-2.66 (-1.68%)

FB

Facebook

$172.17

-0.35 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

HON

Honeywell

$139.09

0.4 (0.29%)

09:48
09/21/17
09/21
09:48
09/21/17
09:48
Recommendations
Honeywell could rally over 14% on portfolio shakeup, says Deutsche Bank »

Honeywell is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBUU

Malibu Boats

$28.53

0.2 (0.71%)

09:48
09/21/17
09/21
09:48
09/21/17
09:48
Periodicals
Breaking Periodicals news story on Malibu Boats »

Malibu Boats mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$10.66

-0.31 (-2.83%)

09:47
09/21/17
09/21
09:47
09/21/17
09:47
Recommendations
GoPro analyst commentary  »

GoPro unit and earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:46
09/21/17
09/21
09:46
09/21/17
09:46
General news
Bloomberg Consumer Comfort Index Level data reported »

Week of 9/17 Bloomberg…

JD

JD.com

$44.44

0.11 (0.25%)

09:45
09/21/17
09/21
09:45
09/21/17
09:45
Recommendations
JD.com analyst commentary  »

JD.com estimates cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
09/21/17
09/21
09:45
09/21/17
09:45
General news
U.S. leading indicators preview: »

U.S. leading indicators…

09:45
09/21/17
09/21
09:45
09/21/17
09:45
General news
Leading Indicators to be reported at 10:00 »

August Leading Indicators…

ALIOF

Actelion

$277.27

-2.73 (-0.98%)

09:45
09/21/17
09/21
09:45
09/21/17
09:45
Conference/Events
Actelion has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

OMP

Oasis Midstream Partners

, OAS

Oasis Petroleum

09:44
09/21/17
09/21
09:44
09/21/17
09:44
Syndicate
Breaking Syndicate news story on Oasis Midstream Partners, Oasis Petroleum »

Oasis Midstream Partners…

OMP

Oasis Midstream Partners

OAS

Oasis Petroleum

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 21

    Sep

MDXG

MiMedx

$12.34

-0.82 (-6.23%)

09:43
09/21/17
09/21
09:43
09/21/17
09:43
Hot Stocks
MiMedx files lawsuit against The Capitol Forum »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

09:42
09/21/17
09/21
09:42
09/21/17
09:42
Technical Analysis
Technical View: Nvidia falls in early trading »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.